kneeEOS is the second offering of the software suite “Cloud Based” 3D surgical planning of EOS to receive the CE mark
Regulatory News:
EOS imaging (Paris: EOSI) (Euronext, FR0011191766 – EOSI), the pioneer of the orthopedic medical imaging 2D / 3D ad today kneeEOS CE marking first 3D planning software for total knee replacement, based on bi-planar EOS images. The company will present kneeEOS 16 th Congress of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) held from 27 to 29 May in Prague.
kneeEOS is the second offering from the portfolio of software applications based on EOS imaging after hipEOS which obtained the CE mark and FDA approval in 2014. These 3D surgical planning software s ‘based on both 2D / 3D EOS low dose and technologies OneFit Medical, a company acquired in 2013 by EOS imaging kneeEOS be deployed as an online service to assist surgeons in the simulation of alignment of the patient’s leg in the operative position, for selection of prosthetic knee implants and for their placement on the basis of 2D / 3D images produced by the EOS system.
Marie Meynadier, Executive Director of EOS imaging, said, “The alignment of the lower limb and optimal implant positioning are recognized as critical for the success of the prosthetic knee surgery. kneeEOS is the first 3D planning software in the upright functional position and we are proud to be, thanks to this new service at the forefront of 3D surgical planning tools, and thus continue to develop the potential of the EOS technology to orthopedic surgeons and their patients. After hipEOS and EOS 3D Service, kneeEOS illustrates the development of our online services, based on unique images provided by EOS and the anatomical markers of patients associated with them. “
EOS® system provides stereo-2D and 3D X-ray images of the entire body of the patient in the operative position, at lower radiation doses from 50% to 85% as the standard X-ray systems, and 95% lower than the doses delivered by the simplest CT scans, as well as related software solutions. The new option Micro Dose EOS recently cleared by the FDA, allows for follow-up examinations of children and teenagers with scoliosis, in accordance with the ALARA (As Low As Reasonably Achievable), at a dose equivalent to that of a natural radiation week on Earth.
For more information about the Company or EOS®, the first 2D imaging system / 3D whole-body low-dose radiation, please visit http: // www .eos-imaging.com
EOS imaging has been selected to join the index EnterNext SMEs © PEA-150, composed of 150 French companies listed on Euronext markets and Alternext . in Paris
EOS imaging is listed on Euronext Paris – Compartment C of Euronext
ISIN: FR0011191766 – Ticker: EOSI
Next press release: Financially the 1 st semester 2015, 20 July 2015 (after the close of financial markets).
About EOS imaging
The EOS imaging group designs, develops and markets EOS®, an innovative imaging medical device based on the work Nobel Prize in Physics Georges Charpak, and related applications. The Group has obtained authorization for placing on the market in 48 countries, including the United States (FDA), Japan, and the European Union (EC). The Group achieved in 2014 a turnover of EUR 20.1 million and employs 107 staff, including R & amp Team; D 39 engineers. The Group is headquartered in Paris and has four subsidiaries: in France in Besançon, in the US in Cambridge, Massachusetts, in Montreal, Canada and Germany in Frankfurt, as well as an office in Singapore.
Visit source version businesswire.com: http://www.businesswire.com/news/home/20150526006063/fr/
No comments:
Post a Comment